{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:44:10Z","timestamp":1765485850098},"reference-count":47,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>In Prader-Willi syndrome (PWS), an altered GH secretion has been related to reduced cardiac mass and systolic function compared to controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The objective was to evaluate the cardiovascular response to a 4-year GH therapy in adult PWS patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Participants:<\/jats:title>\n                  <jats:p>Study participants were nine severely obese PWS adults (three females, six males) and 13 age-, gender-, and body mass index-matched obese controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>In an open-label prospective study, assessment of endocrine parameters and metabolic outcome, whole-body and abdominal fat scans, echocardiography, and radionuclide angiography in unstimulated and dobutamine-stimulated conditions were conducted at baseline and after 1 and 4 years of GH treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>GH treatment increased IGF-1 (P &amp;lt; .0001), decreased C-reactive protein levels (P &amp;lt; .05), improved visceral fat mass (P &amp;lt; .05), and achieved near-significant changes of fat and fat-free body mass in PWS patients. Left ventricle mass indexed by fat mass increased significantly after 1 and 4 years of GH therapy (P &amp;lt; .05) without evident abnormalities of diastolic function, while a trend toward a reduction of the ejection fraction was documented by echocardiography (P = .054). Radionuclide angiography revealed stable values throughout the study of both the left and right ventricle ejection fractions, although this was accompanied by a statistically nonsignificant reduction of the left ventricle filling rate. A positive association between lean body mass and left ventricle ejection fraction was evident during the study (P &amp;lt; .05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>GH therapy increased the cardiac mass of PWS adults without causing overt abnormalities of systolic and diastolic function. Although the association between lean mass and left ventricle ejection fraction during GH therapy corroborates a favorable systemic outcome of long-term GH treatment in adults with PWS, subtle longitudinal modifications of functional parameters advocate appropriate cardiac monitoring in the long-term therapeutic strategy for PWS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2015-1063","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T18:11:52Z","timestamp":1424801512000},"page":"2106-2114","source":"Crossref","is-referenced-by-count":12,"title":["Long-term Echocardiographic and Cardioscintigraphic Effects of Growth Hormone Treatment in Adults With Prader-Willi Syndrome"],"prefix":"10.1210","volume":"100","author":[{"given":"Paolo","family":"Marzullo","sequence":"first","affiliation":[{"name":"Departments of General Medicine (P.M., M.S.), I-28921 Verbania, Italy;"},{"name":"Department of Translational Medicine (P.M., G.A.), Universit\u00e0 del Piemonte Orientale, I-28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Marcassa","sequence":"additional","affiliation":[{"name":"Departments of Cardiology (C.M., E.E.), I-27100 Veruno, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Minocci","sequence":"additional","affiliation":[{"name":"Metabolic Rehabilitation (A.M., A.S.), I-28921 Verbania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Campini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine (R.C.), Fondazione Salvatore Maugeri, I-27100 Veruno, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermanno","family":"Eleuteri","sequence":"additional","affiliation":[{"name":"Departments of Cardiology (C.M., E.E.), I-27100 Veruno, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca Alessandro","family":"Gondoni","sequence":"additional","affiliation":[{"name":"Cardiac Rehabilitation (L.A.G.), I-28921 Verbania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Aimaretti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (P.M., G.A.), Universit\u00e0 del Piemonte Orientale, I-28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sartorio","sequence":"additional","affiliation":[{"name":"Metabolic Rehabilitation (A.M., A.S.), I-28921 Verbania, Italy;"},{"name":"Auxology (A.S., G.G.), Ospedale San Giuseppe, Instituto di Ricovero e Cura a Carattere Scientifico Istituto Auxologico Italiano, I-28921 Verbania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Scacchi","sequence":"additional","affiliation":[{"name":"Departments of General Medicine (P.M., M.S.), I-28921 Verbania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziano","family":"Grugni","sequence":"additional","affiliation":[{"name":"Auxology (A.S., G.G.), Ospedale San Giuseppe, Instituto di Ricovero e Cura a Carattere Scientifico Istituto Auxologico Italiano, I-28921 Verbania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071619043981800_B1","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jcem.87.8.8735","article-title":"Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity","volume":"87","author":"H\u00f6ybye","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"Prader-Willi syndrome","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet Med"},{"key":"2020071619043981800_B3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.numecd.2012.11.006","article-title":"Metabolic syndrome in adult patients with Prader-Willi syndrome","volume":"23","author":"Grugni","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2020071619043981800_B4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2265.2006.02621.x","article-title":"Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome","volume":"65","author":"Grugni","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071619043981800_B5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000323442","article-title":"The GH\/IGF-I axis and pituitary function and size in adults with Prader-Willi syndrome","volume":"75","author":"van Nieuwpoort","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"2020071619043981800_B6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/oby.2006.193","article-title":"Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity","volume":"14","author":"Theodoro","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"2020071619043981800_B7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-2007-978698","article-title":"The role of the GH\/IGF-I axis for cardiac function and structure","volume":"31","author":"Isgaard","year":"1999","journal-title":"Horm Metab Res"},{"key":"2020071619043981800_B8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/cen.12142","article-title":"Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls","volume":"79","author":"Grugni","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071619043981800_B9","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1210\/jc.2012-3888","article-title":"Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome","volume":"98","author":"Deal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2009-1389","article-title":"Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome","volume":"95","author":"Carrel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B11","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1210\/jc.2013-2012","article-title":"Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects","volume":"98","author":"Bakker","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B12","doi-asserted-by":"crossref","first-page":"E328","DOI":"10.1210\/jc.2012-2881","article-title":"Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood","volume":"98","author":"Coupaye","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1651-2227.2006.00051.x","article-title":"Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome","volume":"96","author":"H\u00f6ybye","year":"2007","journal-title":"Acta Paediatr"},{"key":"2020071619043981800_B14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12020-011-9560-4","article-title":"Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study","volume":"41","author":"Sode-Carlsen","year":"2012","journal-title":"Endocrine"},{"key":"2020071619043981800_B15","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1210\/jc.2013-3607","article-title":"Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with Prader-Willi syndrome","volume":"99","author":"Lafortuna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajmg.a.36355","article-title":"Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome","volume":"164A","author":"Oto","year":"2014","journal-title":"Am J Med Genet A"},{"key":"2020071619043981800_B17","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1111\/j.1651-2227.2011.02570.x","article-title":"Cardiac evaluation in children with Prader-Willi syndrome","volume":"101","author":"Marcus","year":"2012","journal-title":"Acta Paediatr"},{"key":"2020071619043981800_B18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2265.2007.02808.x","article-title":"Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome","volume":"66","author":"Patel","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071619043981800_B19","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1210\/jc.2005-0829","article-title":"The impact of growth hormone\/insulin-like growth factor-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi syndrome","volume":"90","author":"Marzullo","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B20","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1210\/jc.2006-0600","article-title":"Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome","volume":"92","author":"Marzullo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B21","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1210\/jcem.87.5.8509","article-title":"Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency","volume":"87","author":"Biller","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1515\/JPEM.2008.21.7.651","article-title":"Successful early dietary intervention avoids obesity in patients with Prader-Willi syndrome: a ten-year follow-up","volume":"21","author":"Schmidt","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071619043981800_B23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ajmg.a.20371","article-title":"Prader-Willi syndrome: causes of death in an international series of 27 cases","volume":"124A","author":"Schrander-Stumpel","year":"2004","journal-title":"Am J Med Genet A"},{"key":"2020071619043981800_B24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ejhg.5201135","article-title":"Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders","volume":"12","author":"Vogels","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"2020071619043981800_B25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajmg.a.30777","article-title":"Cause of sudden, unexpected death of Prader-Willi syndrome patients with or without growth hormone treatment","volume":"136","author":"Nagai","year":"2005","journal-title":"Am J Med Genet A"},{"key":"2020071619043981800_B26","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ajmg.a.34171","article-title":"Physical health problems in adults with Prader-Willi syndrome","volume":"155A","author":"Sinnema","year":"2011","journal-title":"Am J Med Genet A"},{"key":"2020071619043981800_B27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ajmg.a.32133","article-title":"The Italian National Survey for Prader-Willi syndrome: an epidemiologic study","volume":"146A","author":"Grugni","year":"2008","journal-title":"Am J Med Genet A"},{"key":"2020071619043981800_B28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1469-8749.1987.tb02129.x","article-title":"Adults with Prader-Willi syndrome: a survey of 232 cases","volume":"29","author":"Greenswag","year":"1987","journal-title":"Dev Med Child Neurol"},{"key":"2020071619043981800_B29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S001216220100202X","article-title":"Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study","volume":"44","author":"Butler","year":"2002","journal-title":"Dev Med Child Neurol"},{"key":"2020071619043981800_B30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/jmg.38.11.792","article-title":"Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK health region","volume":"38","author":"Whittington","year":"2001","journal-title":"J Med Genet"},{"key":"2020071619043981800_B31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071619043981800_B32","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1161\/01.CIR.0000100720.01867.1D","article-title":"Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis","volume":"108","author":"Maison","year":"2003","journal-title":"Circulation"},{"key":"2020071619043981800_B33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000319612","article-title":"Effects of growth hormone therapy on cardiac dimensions in children and adolescents with Prader-Willi syndrome","volume":"75","author":"Hauffa","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"2020071619043981800_B34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1210\/edrv-15-5-555","article-title":"Growth hormone and the heart","volume":"15","author":"Sacc\u00e0","year":"1994","journal-title":"Endocr Rev"},{"key":"2020071619043981800_B35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00414-004-0513-9","article-title":"Sudden cardiac death in a child affected by Prader-Willi syndrome","volume":"119","author":"Pomara","year":"2005","journal-title":"Int J Legal Med"},{"key":"2020071619043981800_B36","doi-asserted-by":"crossref","first-page":"384167","DOI":"10.1155\/2013\/384167","article-title":"Effects of adiposity and Prader-Willi Syndrome on postexercise heart rate recovery","volume":"2013","author":"Castner","year":"2013","journal-title":"J Obes"},{"key":"2020071619043981800_B37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/cen.12084","article-title":"Postprandial cardiac autonomic function in Prader-Willi syndrome","volume":"79","author":"Purtell","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071619043981800_B38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1164\/ajrccm.153.1.8542130","article-title":"Arousal and cardiorespiratory responses to hypoxia in Prader-Willi syndrome","volume":"153","author":"Arens","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071619043981800_B39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2169\/internalmedicine.52.8659","article-title":"Successful treatment of heart failure in an adult patient with Prader-Willi syndrome","volume":"52","author":"Kawano","year":"2013","journal-title":"Intern Med"},{"key":"2020071619043981800_B40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1651-2227.1999.tb14415.x","article-title":"Body composition in Prader-Willi syndrome: assessment and effects of growth hormone administration","volume":"88","author":"Davies","year":"1999","journal-title":"Acta Paediatr Suppl"},{"key":"2020071619043981800_B41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1651-2227.1999.tb14416.x","article-title":"Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group","volume":"88","author":"Lindgren","year":"1999","journal-title":"Acta Paediatr Suppl"},{"key":"2020071619043981800_B42","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/jcem.87.4.8414","article-title":"Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study","volume":"87","author":"Carrel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2265.2003.01769.x","article-title":"Growth hormone treatment improves body composition in adults with Prader-Willi syndrome","volume":"58","author":"H\u00f6ybye","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071619043981800_B44","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.neubiorev.2012.05.005","article-title":"The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: a systematic review","volume":"36","author":"Reus","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"2020071619043981800_B45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1210\/jc.2007-2212","article-title":"Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial","volume":"93","author":"Mogul","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B46","doi-asserted-by":"crossref","first-page":"E1727","DOI":"10.1210\/jc.2014-2059","article-title":"Dual-energy x-ray absorptiometry is a valid method to estimate visceral adipose tissue in adult patients with Prader-Willi syndrome during treatment with growth hormone","volume":"99","author":"Olarescu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619043981800_B47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF03349255","article-title":"Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome","volume":"31","author":"Gondoni","year":"2008","journal-title":"J Endocrinol Invest"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/5\/2106\/10855190\/jcem2106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/5\/2106\/10855190\/jcem2106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:16:55Z","timestamp":1594959415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/100\/5\/2106\/2829736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2015-1063","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]}}}